

Modification of Drug Particle Morphology by Spherical Crystallization Technique to Obtain Directly Compressible Material

S Jyothi*

Department of Pharmaceutics, MRM College of pharmacy, Hyderabad, Telangana, India

Research Article

Received: 26/08/2021

Accepted: 09/09/2021

Published: 16/09/2021

***For correspondence:**

S Jyothi, Department of Pharmaceutics, MRM College of pharmacy, Hyderabad, Telangana, India

E-mail: ellurujyothi@gmail.com

Keywords: Direct compression; Spherical crystallization; Spherical agglomeration; Bridging liquid; Particle design

ABSTRACT

Spherical crystallization is a novel particle engineering/design technique developed by Kawashima et al, to overcome the problems associated with direct compression. Basically, it's single step process used for size enlargement of single, two or more, small dose or large dose drugs, in combination with or without diluent. The process of spherical crystallization involves simultaneous crystallization and agglomeration of drug/s with/without excipients/s from good solvent and/or bridging liquid by addition of a non-solvent. The spherical agglomerates obtained by spherical crystallization can be directly compressible tablet intermediates having satisfactory micromeritic (flow ability), mechanical (friability, crushing), compressional (compressibility, compatibility), and drug release properties. Enhanced drug release from agglomerates and compacts thereof can be achieved using suitable polymer composition in the process design. Thus, it can be concluded that, spherical crystallization is a simple and cost effective process, which can be modify the morphology for particle design of all majority of drugs and combinations.

INTRODUCTION

Tablets are the solid unit dosage forms of choice with good dose precision and least content variability, low cost, ease of administration and tamper proof packaging. Over the last several decades tablets have undergone rapid developmental changes and direct compression is one of the most revolutionary technologies. Direct compression is the modern most efficient process of tablet manufacturing and offer advantages like it is economical, facilitates

processing without the need of moisture and heat, less number of processing steps and able to form stable compacts at low punch forces. Spherical crystallization is one of technique of particle design and a non convective method imparts the properties like good flow ability, mechanical strength, compressibility and enhance the particle size and eliminates many processing steps like granulation and drying etc. moreover for moisture sensitive drugs wet granulation cannot be applied. Spherical crystallization can be employed for some of the drugs such as NSAIDS which exhibit the poor compressibility, flow ability, solubility and for drugs are not suitable for direct compression. Recently in pharmaceutical companies for reducing the production cost and improving the production process by modified crystalline technique were used spherical crystallization is one among those techniques which has emerged as one of the areas of active research ,currently of interest in pharmaceutical manufacturing and recently came into forefront of interest and gained attention and importance due to the fact of crystal habit(form, surface, size and particle size distribution can be modified during the crystallization process. When large amount of non water soluble drugs with poor rheological properties are needed to be formulated the quality and efficiency of solid dosage form is influenced by primary micrometric properties (size and shape of crystals) and micromeritic properties(bulk density, flow ability) of active medical substances and inactive substances.

MATERIALS AND METHODS

Spherical crystallization enables co-precipitation of drug and encapsulating polymer in the form of spherical particles. Spherical agglomeration technique is beneficial to ease of formulating microspheres, microsponges, nanospheres, microballoons and nanoparticles which acts as novel particulate drug delivery systems. To improve bioavailability as crystalline form is converted into different polymorphic forms, enables the improvement of flow ability and compressibility of crystalline drugs, it has been successfully employed to enable processes such as separation, filtration, drying etc. to be carried out more efficiently, drastically improves wettability, dissolution rate and can be easily compounded with other pharmaceutical powders (Table 1) [4].

Table 1. It shows drug solubility and selection of solvents, bridging liquid and methods.


Drug solubility	Continuous phase	Bridging liquid	Method applied
In water	Water immiscible organic solvent	Calcium chloride solution (20%)	Spherical agglomeration technique
In organic solvent	Water	Water immiscible organic solvent	Spherical agglomeration technique
Water miscible organic solvent	Saturated aqueous organic solution	Organic solvent mixture	Quasi-emulsion solvent diffusion method
Water or any other organic solvent	Water immiscible organic solvent	Calcium chloride solution (20%)+binding solution	Spherical agglomeration technique

Solvent change method involves simultaneous crystallization and agglomeration of two or more drugs from a good solvent and bridging liquid by addition of a non-solvent. To obtain fine crystals the solution of the drug and a good solvent is poured into a poor solvent under controlled condition of temperature and speed. The bridging liquid is used for agglomeration of the crystals. The poor solvent has miscibility with good solvent but has low solubility in solvent mixture, so that, during agitation of the solvent system the crystals are formed. The drawback of this system is that it provides low yield, due to co-solvency effect of crystallization solvent. The bridging liquid, the stirring speed and the concentration of solids are the influencing factors for the spherical crystallization.

Lesser amount of bridging liquid will yield fine particles whereas larger amount of bridging liquid will produce coarse particles. By increasing stirring rate the agglomeration get reduced, because of increasing disruptive forces. Porosity decreases when the concentration of solid increases. The viscosity of the continuous phase has an effect on the size distribution of the agglomerates. The choice of bridging liquid has an influence on the rate of agglomeration and also on the strength of the agglomerates.

In the case of quasi emulsion solvent diffusion method, affinity between the drug and a good solvent is stronger than that of the drug and poor solvent. Residual good solvent in droplets acts as a bridging liquid to agglomerate the generated crystals. Due to the interfacial tension between the two solvents, the good solvent diffuses gradually out of the emulsion droplet into the outer poor solvent phase. The crystallization of drug occurs by counter diffusion of good solvent and poor solvent. In this process, the emulsion is stabilized by the selection of suitable polymer which is required for proper crystallization. In the droplets, the process of solidification proceeds inwards and the liquid are not maintained on the surface and the agglomerate formed without coalescence (Figure 1) [2].


Figure 1. It shows Mechanism of Quasi emulsion solvent diffusion method.



Ammonia diffusion

In this method, the mixture of acetone, ammonia water and dichloromethane shall be used as a crystallization system. In this system ammonia water acts as bridging liquid as well as good solvent. The other components of the system, like poor solvent and a hydrocarbon derivative are selected depending upon the drug's solubility in that solvent. Acetone (hydrocarbon derivative) is miscible with the system but it reduces the miscibility of ammonia water with poor solvent. The ammonia water exists as immiscible phase forming droplets. The counter diffusion process across the droplet involves movement of poor solvent into and ammonia out of the droplet. Inside the droplet agglomeration takes place as the drug precipitates slowly in ammonia water and causes growth of crystal. The technique is mainly applicable for amphoteric drugs, which have the same properties as enoxacin (Figure 2) [3].

Figure 2. It shows Mechanism of Ammonia diffusion method.



RESULTS AND DISCUSSION

Neutralization

The method consists of dissolving the drug in the good solvent and placing in the cylindrical vessel with constant stirring. During stirring an aqueous polymer solution and one neutral solution was added to neutralize the good solvent, which crystallizes out the drug. The bridging liquid shall be added drop wise at a definite rate. The agglomeration of the crystal form of the drug takes place.

Traditional crystallization process

Spherical agglomerates shall be produced in these methods by controlling the physical and chemical properties and can be called as the non typical spherical crystallization processes

Crystal-co-agglomeration technique

Applications of spherical crystallization to obtain directly compressible agglomerates without diluents are restricted to water insoluble large-dose drugs only. Most of the excipients, such as diluents and disintegrating agents, are hydrophilic in nature. Hence incorporation of these excipients in the agglomerates formed by using organic bridging liquid is difficult. Due to this limitation, spherical crystallization could not be applied to obtain agglomerates of low-dose or poorly compressible materials. To overcome these limitations of spherical crystallization. Developed the Crystallo Co-Agglomeration (CCA) technique. It is a modification of the spherical crystallization technique in which a drug is crystallized and agglomerated with excipients or with another drug, which may or may not be crystallized in the system. The agglomeration is performed using bridging liquid. The process enables design of agglomerates containing two drugs or a low-dose or poorly compressible drug in combination with diluents. The difference in the physicochemical properties of the drug molecules and the excipients become the major challenge in the selection of a solvent system for the crystal-co-agglomeration technique.

Thin layer chromatography

TLC study was carried out in mentioned mobile phase and the R_f value was determined and compared the R_f value of drug with the spherical crystals. This study was carried out to check the interaction between the drug and the polymer and also to confirm the stability of drug in solvents.

Fourier Transform Infrared spectrometer

It was done for identification of the drug present and also to identify whether the drug has undergone polymorphism. It is much more useful for distinguishing between solvates and anhydrous form then for identifying polymorphs because of the addition of new stretching frequencies resulting from the solvation.

Differential scanning calorimeter

Differential Scanning Calorimeter (DSC) measures the heat loss or gain resulting due to physical or chemical changes within a sample could be obtained from thermograms using instrumental software. If a mixture of drugs and polymer is agglomerated together then change in properties of agglomerates can be studied with DSC. It is also useful to determine thermal degradation, purity, polymorphism, solvation, Dehydration, Dissociation, Decomposition, and Phase transfer, Glass transition, Heat capacity and drug-excipients compatibility. Crystal of samples are heated (25 °C to 200 °C) at the rate of 10 °C/min in crimped hermetically sealed aluminum pans under nitrogen atmosphere. Calorimeter was calibrated using Indium and lead standards.

Geometrical properties of agglomerates

Geometrical properties of spherical crystals can be determined by image processing system. Around 300 particles of different range size fraction were run over with an optical pen. The system determines the smallest (D_{min}) and the largest (D_{max}) diameter of each individual particle. A Parameter R was developed, which indicates the roundness of the particles sovereignty of the size of the particle. A value of R near 1 is indicative of perfectly spherical agglomerate.


Electron Scanning Microscopy

The surface topography, type of crystals (polymorphism and crystal habit) of the spherical agglomerates and the conventional crystals is analyzed by using scanning electron microscopy. Using an image analyzer micrographs of more than 100 particles were transformed into the software and the shape factor is specified as 4π (area/perimeter).

- Parameters determining the agglomerates behavior
- Particle size, Particle shape and Size distribution
- Change of crystal habit of pharmaceuticals gives different physico-chemical properties.
- Size and crystal habit of pharmaceuticals changes on recrystallization in spherical crystallization.
- In advance technology, Size and volume of particles can be determined by image analyzer.
- Size of particles and their distributions can be determined by simple sieve analysis.
- Particle size analysis can be determined by Ro-Tap sieve shaker.

The moisture uptake is determined by taking the weighed quantity of drug and spherical crystals and placing them in crucible at accelerated conditions of temperature and humidity i.e., $40 \pm 10^\circ\text{C}$ and $75 \pm 3\%$ respectively. The weight gain of drug and spherical crystals is measured (Figure 3) [4].

Figure 3. It shows Wettability and contact angles.



Mechanical strength

Tensile strength: Tensile strength of spherical crystals is measured by applying maximum load required to crush the spherical crystal. This method is a direct method to measure the tensile strength of spherical crystals.


Crushing strength: It is measured by using 50ml glass hypodermic syringe. The modification includes the removal of the tip of the syringe barrel and the top end of the plunger. The barrel is then used as hollow support and the guide tube with close fitting tolerances to the Plunger. The hollow plunger with open end served as load cell in which mercury could be added. A window cut into the barrel to facilitate placement of granule on the base platen. The plunger acted as movable plates and set directly on the granules positioned on the lower platen as the rate of loading may affect crushing load (gm). At the rate of 10 gm/sec, mercury is introduced from reservoir into the upper chamber until the single granule crushed; loading time should be <3 minutes. The total weight of the plunger and the mercury required to fracture a granule is the crushing load.

Compression behavior analysis

Good compatibility and compressibility are the fundamental properties of directly compressible crystals. The compaction behavior of agglomerated crystals and single crystals is obtained by plotting a graph by taking the relative volume against the compression pressure. Spherical agglomerates possess superior strength characteristics in comparison to conventional crystals. The surface are freshly prepared by fracture during

compression of agglomerates, which intensifies the plastic inter particle bonding, resulting in a lower compression force obligatory for compressing the agglomerates under plastic deformation compared to that of single crystals. Compaction behavior of agglomerated crystals were evaluated by using following parameters (Figure 4) [5].

Figure 4. It shows Compression of the spherical agglomerates.



CONCLUSION

Impose specific quantity of spherical agglomerated crystals sample in a die of specific diameter, magnesium stearate was coated on the surface of die in advance, then used the universal tensile compression tester to compress the samples at a constant speed. After the certain limit of pressure attained, the upper punch held in the same position for 20 min, during which measured time for the reduction amount of the stress applied on the upper punch. The result corrected by subtracting from this measurement the relaxation measured without powder in the die under the same conditions. The relationship between relaxation ratio $Y(t)$ and time t , calculated the parameters A_s and B_s , and assessed relaxation.

REFERENCES

1. Gocz H, et al. Development of spherical crystallization of acetyl salicylic acid for direct tablet making. *Chem Pharm Bull.* 2000;48(12):1877-1881.
2. Yadav VB, et al. Comparative tableting behavior of carbamazepine granules with spherical agglomerated crystals prepared by spherical crystallization technique. *Int J Chem Tech Res.* 2009; 1(3): 476-482.
3. Kuriki ST, et al. Particle design of tolbutamide in presence of soluble polymers or surfactants by spherical crystallization technique. Improvement of dissolution rate. *J Pharm Sci.* 1987;76(6):471-482.
4. Kawashima Y. Development of Spherical crystallization technique and its application to pharmaceutical systems. *Arch Pharm Res.* 1984;7(2): 145-151.
5. Blandin AF, et al. Agglomeration in suspension of salicylic acid fine particles: Influence of some process parameters on kinetics and agglomerate final size. *Powder Technol.* 2003;130:316-323.